CN109350652A - The composition of improvement menopause symptom containing NADH, preparation and the preparation method and application thereof - Google Patents
The composition of improvement menopause symptom containing NADH, preparation and the preparation method and application thereof Download PDFInfo
- Publication number
- CN109350652A CN109350652A CN201810514788.6A CN201810514788A CN109350652A CN 109350652 A CN109350652 A CN 109350652A CN 201810514788 A CN201810514788 A CN 201810514788A CN 109350652 A CN109350652 A CN 109350652A
- Authority
- CN
- China
- Prior art keywords
- parts
- weight
- preparation
- composition
- symptom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000024891 symptom Diseases 0.000 title claims abstract description 69
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 title claims abstract description 47
- 238000002360 preparation method Methods 0.000 title claims abstract description 44
- 230000009245 menopause Effects 0.000 title claims abstract description 43
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 title claims abstract description 40
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- 230000006872 improvement Effects 0.000 title claims abstract description 28
- 239000003814 drug Substances 0.000 claims abstract description 27
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229960001570 ademetionine Drugs 0.000 claims abstract description 10
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims abstract description 9
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims abstract description 9
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims abstract description 9
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 claims abstract description 9
- 229960001661 ursodiol Drugs 0.000 claims abstract description 9
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229920001287 Chondroitin sulfate Polymers 0.000 claims abstract description 8
- 229940059329 chondroitin sulfate Drugs 0.000 claims abstract description 8
- 239000000463 material Substances 0.000 claims description 34
- 239000002994 raw material Substances 0.000 claims description 22
- 229940088594 vitamin Drugs 0.000 claims description 18
- 229930003231 vitamin Natural products 0.000 claims description 18
- 235000013343 vitamin Nutrition 0.000 claims description 18
- 239000011782 vitamin Substances 0.000 claims description 18
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 18
- 239000006228 supernatant Substances 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 210000000582 semen Anatomy 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 238000000605 extraction Methods 0.000 claims description 13
- 239000000843 powder Substances 0.000 claims description 13
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 12
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 claims description 12
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 11
- 239000002775 capsule Substances 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 11
- 235000013399 edible fruits Nutrition 0.000 claims description 11
- 238000001914 filtration Methods 0.000 claims description 11
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 10
- 238000005303 weighing Methods 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 9
- 238000010992 reflux Methods 0.000 claims description 9
- 239000000341 volatile oil Substances 0.000 claims description 9
- 241000605447 Anemarrhena Species 0.000 claims description 8
- 235000019441 ethanol Nutrition 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 8
- 150000002148 esters Chemical class 0.000 claims description 7
- 239000000047 product Substances 0.000 claims description 7
- 241000167550 Centella Species 0.000 claims description 6
- 229920001353 Dextrin Polymers 0.000 claims description 6
- 239000004375 Dextrin Substances 0.000 claims description 6
- 229910019142 PO4 Inorganic materials 0.000 claims description 6
- 240000002924 Platycladus orientalis Species 0.000 claims description 6
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 6
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 6
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 6
- 235000019425 dextrin Nutrition 0.000 claims description 6
- 239000001530 fumaric acid Substances 0.000 claims description 6
- 229910021485 fumed silica Inorganic materials 0.000 claims description 6
- 239000003292 glue Substances 0.000 claims description 6
- 210000000569 greater omentum Anatomy 0.000 claims description 6
- 235000019359 magnesium stearate Nutrition 0.000 claims description 6
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 6
- 239000010452 phosphate Substances 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 6
- 235000021317 phosphate Nutrition 0.000 claims description 6
- 239000013049 sediment Substances 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 229940026510 theanine Drugs 0.000 claims description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 6
- 239000000811 xylitol Substances 0.000 claims description 6
- 235000010447 xylitol Nutrition 0.000 claims description 6
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 6
- 229960002675 xylitol Drugs 0.000 claims description 6
- 244000061520 Angelica archangelica Species 0.000 claims description 5
- 241001546929 Campsis grandiflora Species 0.000 claims description 5
- 240000004307 Citrus medica Species 0.000 claims description 5
- 102000008186 Collagen Human genes 0.000 claims description 5
- 108010035532 Collagen Proteins 0.000 claims description 5
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims description 5
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims description 5
- 235000009685 Crataegus X maligna Nutrition 0.000 claims description 5
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims description 5
- 235000009486 Crataegus bullatus Nutrition 0.000 claims description 5
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims description 5
- 235000009682 Crataegus limnophila Nutrition 0.000 claims description 5
- 240000000171 Crataegus monogyna Species 0.000 claims description 5
- 235000004423 Crataegus monogyna Nutrition 0.000 claims description 5
- 235000002313 Crataegus paludosa Nutrition 0.000 claims description 5
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims description 5
- 235000014375 Curcuma Nutrition 0.000 claims description 5
- 244000163122 Curcuma domestica Species 0.000 claims description 5
- 241000207901 Cuscuta Species 0.000 claims description 5
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 5
- 240000000249 Morus alba Species 0.000 claims description 5
- 235000008708 Morus alba Nutrition 0.000 claims description 5
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 5
- 240000005001 Paeonia suffruticosa Species 0.000 claims description 5
- 235000003889 Paeonia suffruticosa Nutrition 0.000 claims description 5
- 240000001341 Reynoutria japonica Species 0.000 claims description 5
- 235000018167 Reynoutria japonica Nutrition 0.000 claims description 5
- 241000219289 Silene Species 0.000 claims description 5
- 241000157352 Uncaria Species 0.000 claims description 5
- 244000126002 Ziziphus vulgaris Species 0.000 claims description 5
- 229910052918 calcium silicate Inorganic materials 0.000 claims description 5
- FEZWOUWWJOYMLT-DSRCUDDDSA-M cobalt;[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7,1 Chemical compound [Co].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FEZWOUWWJOYMLT-DSRCUDDDSA-M 0.000 claims description 5
- 229960000304 folic acid Drugs 0.000 claims description 5
- 235000019152 folic acid Nutrition 0.000 claims description 5
- 239000011724 folic acid Substances 0.000 claims description 5
- 235000011087 fumaric acid Nutrition 0.000 claims description 5
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 5
- 239000000347 magnesium hydroxide Substances 0.000 claims description 5
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 5
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- -1 sorbitan fatty acid ester Chemical class 0.000 claims description 5
- 241000821414 Aquilegia yabeana Species 0.000 claims description 4
- 241000218176 Corydalis Species 0.000 claims description 4
- 241000208421 Ericaceae Species 0.000 claims description 4
- 241000202807 Glycyrrhiza Species 0.000 claims description 4
- 241000096284 Gynochthodes officinalis Species 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 230000036541 health Effects 0.000 claims description 4
- 235000008216 herbs Nutrition 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 239000007901 soft capsule Substances 0.000 claims description 4
- 229940100515 sorbitan Drugs 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 238000007873 sieving Methods 0.000 claims description 3
- 239000000741 silica gel Substances 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- 238000004513 sizing Methods 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 3
- 238000010792 warming Methods 0.000 claims description 3
- 244000025254 Cannabis sativa Species 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 229910052709 silver Inorganic materials 0.000 claims description 2
- 239000004332 silver Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 2
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 claims 1
- 240000007185 Albizia julibrissin Species 0.000 claims 1
- 235000011468 Albizia julibrissin Nutrition 0.000 claims 1
- 235000002710 Ilex cornuta Nutrition 0.000 claims 1
- 241001310146 Ilex cornuta Species 0.000 claims 1
- 241001506304 Kadsura japonica Species 0.000 claims 1
- 244000241838 Lycium barbarum Species 0.000 claims 1
- 235000015459 Lycium barbarum Nutrition 0.000 claims 1
- 235000010326 Osmanthus heterophyllus Nutrition 0.000 claims 1
- 229910021529 ammonia Inorganic materials 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 238000004132 cross linking Methods 0.000 claims 1
- 238000012856 packing Methods 0.000 claims 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 16
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical group N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 abstract description 10
- 238000009472 formulation Methods 0.000 abstract description 5
- 230000008569 process Effects 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 230000002411 adverse Effects 0.000 abstract description 2
- 230000008878 coupling Effects 0.000 abstract description 2
- 238000010168 coupling process Methods 0.000 abstract description 2
- 238000005859 coupling reaction Methods 0.000 abstract description 2
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 2
- 238000011282 treatment Methods 0.000 description 33
- 230000000694 effects Effects 0.000 description 21
- 206010027304 Menopausal symptoms Diseases 0.000 description 14
- 208000011580 syndromic disease Diseases 0.000 description 11
- 230000006870 function Effects 0.000 description 10
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 229950006238 nadide Drugs 0.000 description 9
- 210000003734 kidney Anatomy 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 108010024137 Nicotinamide-Nucleotide Adenylyltransferase Proteins 0.000 description 7
- 102000015597 Nicotinamide-nucleotide adenylyltransferase Human genes 0.000 description 7
- 206010037660 Pyrexia Diseases 0.000 description 7
- 239000000262 estrogen Substances 0.000 description 7
- 229940011871 estrogen Drugs 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000002398 materia medica Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 229920002785 Croscarmellose sodium Polymers 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 210000001672 ovary Anatomy 0.000 description 5
- 240000000559 Albizia odoratissima Species 0.000 description 4
- 235000011438 Albizia odoratissima Nutrition 0.000 description 4
- 206010003439 Artificial menopause Diseases 0.000 description 4
- 244000025670 Eleusine indica Species 0.000 description 4
- 235000014716 Eleusine indica Nutrition 0.000 description 4
- 241000628997 Flos Species 0.000 description 4
- 241001506371 Kadsura Species 0.000 description 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 229960001681 croscarmellose sodium Drugs 0.000 description 4
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000005728 strengthening Methods 0.000 description 4
- 241000721047 Danaus plexippus Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- TZJALUIVHRYQQB-XFDQAQKOSA-N Icariin Natural products O(C)c1ccc(C2=C(O[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)C(=O)c3c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)c(C/C=C(\C)/C)c3O2)cc1 TZJALUIVHRYQQB-XFDQAQKOSA-N 0.000 description 3
- 239000006137 Luria-Bertani broth Substances 0.000 description 3
- DAYLJWODMCOQEW-TURQNECASA-N NMN zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)([O-])=O)O2)O)=C1 DAYLJWODMCOQEW-TURQNECASA-N 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 239000000287 crude extract Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 238000011010 flushing procedure Methods 0.000 description 3
- 210000002149 gonad Anatomy 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- TZJALUIVHRYQQB-XLRXWWTNSA-N icariin Chemical compound C1=CC(OC)=CC=C1C1=C(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)C(=O)C2=C(O)C=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-XLRXWWTNSA-N 0.000 description 3
- TZJALUIVHRYQQB-UHFFFAOYSA-N icariine Natural products C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(C)O2)O)C(=O)C2=C(O)C=C(OC3C(C(O)C(O)C(CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-UHFFFAOYSA-N 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000012254 magnesium hydroxide Nutrition 0.000 description 3
- 230000000422 nocturnal effect Effects 0.000 description 3
- 210000002394 ovarian follicle Anatomy 0.000 description 3
- 230000027758 ovulation cycle Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- NGMYNFJANBHLKA-SENBMHEBSA-N Icariside II Natural products O(C)c1ccc(C2=C(O[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)C(=O)c3c(O)cc(O)c(C/C=C(\C)/C)c3O2)cc1 NGMYNFJANBHLKA-SENBMHEBSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- 206010026749 Mania Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000002657 hormone replacement therapy Methods 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- NGMYNFJANBHLKA-LVKFHIPRSA-N icariside II Chemical compound C1=CC(OC)=CC=C1C1=C(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)C(=O)C2=C(O)C=C(O)C(CC=C(C)C)=C2O1 NGMYNFJANBHLKA-LVKFHIPRSA-N 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004914 menses Anatomy 0.000 description 2
- 235000020956 nicotinamide riboside Nutrition 0.000 description 2
- 239000011618 nicotinamide riboside Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000000583 progesterone congener Substances 0.000 description 2
- 238000004080 punching Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 230000036299 sexual function Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- CHZJRGNDJLJLAW-RIQJQHKOSA-N (8r,9s,13s,14s,16r,17r)-3-cyclopentyloxy-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-16,17-diol Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1C[C@@H](O)[C@@]4(O)C#C)C)CC2=CC=3OC1CCCC1 CHZJRGNDJLJLAW-RIQJQHKOSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- 102000057234 Acyl transferases Human genes 0.000 description 1
- 108700016155 Acyl transferases Proteins 0.000 description 1
- QGXLVXZRPRRCRP-IDIVVRGQSA-L Adenosine 5'-phosphate disodium Chemical compound [Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])([O-])=O)[C@@H](O)[C@H]1O QGXLVXZRPRRCRP-IDIVVRGQSA-L 0.000 description 1
- 108010039224 Amidophosphoribosyltransferase Proteins 0.000 description 1
- 208000012219 Autonomic Nervous System disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 244000077995 Coix lacryma jobi Species 0.000 description 1
- 235000007354 Coix lacryma jobi Nutrition 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 206010051131 Mastoptosis Diseases 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- JLEBZPBDRKPWTD-TURQNECASA-O N-ribosylnicotinamide Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 JLEBZPBDRKPWTD-TURQNECASA-O 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 241000736199 Paeonia Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
- 241000736246 Pyrola Species 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 206010071018 Urogenital atrophy Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010047791 Vulvovaginal dryness Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 229960001384 adenosine phosphate disodium Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 102000006995 beta-Glucosidase Human genes 0.000 description 1
- 108010047754 beta-Glucosidase Proteins 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- 229960000452 diethylstilbestrol Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000003694 hair properties Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000007106 menorrhagia Diseases 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000003557 neuropsychological effect Effects 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229950007863 nilestriol Drugs 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/69—Polygalaceae (Milkwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The composition of the improvement menopause symptom containing NADH that the invention discloses a kind of, preparation and the preparation method and application thereof are related to medicine and healthcare field.Composition includes component: the γ-aminobutyric acid of remote, 1-10 parts by weight DHA, 1-10 parts by weight of the Herba Epimedii secondary aglycon of NADH, 1-10 parts by weight of 1-10 parts by weight, the chondroitin sulfate of 1-10 parts by weight, the ursodesoxycholic acid of 1-10 parts by weight, the Sialic acid of 1-10 parts by weight, the s- Ademetionine of 1-10 parts by weight, the will of 1-10 parts by weight.Technical solution of the present invention, each component is played a role using suitable proportion compatibility, collaboration in composition, safety, without adverse affects comprehensive improvement menopause symptom.Formulation preparation method process flow of the invention is simple, the process time is short, no coupling product, and production cost is low, it is easy to accomplish large-scale production.
Description
Technical field
The present invention relates to medicine and healthcare field more particularly to a kind of combinations of the improvement menopause symptom containing NADH
Object, preparation and the preparation method and application thereof.
Background technique
Menopausal syndrome is also known as perimenopausal syndrome, is by occurring sex hormone fluctuation before and after postmenopausal women or reducing institute
What is caused is a series of based on function disorder of autonomic nervous system, with one group of syndrome of neuropsychological symptom.Menopause can be divided into
Natural menopause and two kinds of artificial menopause.Natural menopause refers to that ovarian follicle is used up in ovary or remaining ovarian follicle loses promoting sexual gland hormone
Reaction, ovarian follicle are no longer developed and are secreted estrogen, cannot stimulate endometrial growth, lead to menopause.Artificial menopause refers to hand
Art cuts off bilateral ovaries or stops ovarian function, such as radiotherapy and chemotherapy with other methods.It individually cuts off uterus and retains
Side or bilateral ovaries person, not as artificial menopause.Menopausal syndrome mostly occurs in 45~55 years old, and most of women may occur in which
Equal symptom, someone have not started to occur, continue to post menopausal 2~3 years weight in menopause transition symptom, and a few peoples are sustainable
Just mitigated or disappeared to 5~10 years symptoms of post menopausal.Artificial menopause person often may occur in which climacteric in 2 weeks after surgery
Syndrome, postoperative 2 months reach peak, sustainable 2 years as long as.Climacteric women due to ovarian function gradually fail until lose,
Cause estrogen secretion levels to decline to a great extent, thus just causes a series of bodies based on vegetative nerve Wen Luan ﹑ dysbolism
The problem of body and spirit.Traditional medicine thinks that climacteric syndrome is that viscera function gradually fails, yin-Yang disequilibrium,
Thus there is flushing Chao Re ﹑ dizziness Tou Zhang ﹑ agitation Yi Nu ﹑ depression You Chou ﹑ Xin to throb with fear Shi Mian ﹑ vaginal dryness Zhuo Re ﹑ waist abdomen Bei Tong ﹑ sclerotin
The symptoms such as loose.Climacteric syndrome torments patient in spirit and animally, and even more serious can also cause a series of old age
Xing Ji Bing ﹑ cancer etc., seriously jeopardizes the health of patient's latter half of one's life.
Country's treatment method major sexual hormonotherapy and medicinal treatment, female-progestogen therapy change in which can dramatically at present
Kind spirit-somatization.Total effective rate 84~97%.But its side effect is also obvious: gastrointestinal side effect and estrogen
Dosage is related with dosage form.But women's tolerance is good.To reduce side reaction, principle of individuation should be followed, using minimum effective agent
Amount is reduced or is discontinued after symptom and sign alleviation.Currently, the drug treatment to female dimacteric syndrome mainly has two
Kind.(1) western medical treatment method: doctor trained in Western medicine thinks that hormone replacement therapy is maximally efficient method, and hormone replacement therapy generally comprises
Estrogen, progestin combinations therapy and estrin treatment is applied alone, can improve the hectic fever of patient, insomnia, tired, mood is depressed,
The symptoms such as the dry pain of emotional agitation, minor depressive, Urogenital atrophy and vagina.(2) Chinese traditional treatment method: Chinese medicine thinks,
Female dimacteric syndrome mostly caused by kidney deficiency, women it is close it is premenopausal after, a virtual loss is appointed in kidney qi degradation, punching, and menses will exhaust, essence and blood
Deficiency, imbalance between YIN and YANG, there is the deficiency of the kidney yin, sun loses hiding or decline of kidney-YANG, passages through which vital energy circulates lose supported in temperature, internal organs qi and blood not phase
It is phenomena such as coordination, not normal so as to cause viscera function.Therefore often there is worried, depressed, irritated, suspicious even happiness anger of worrying too much
The symptoms such as impermanence.The treatment method of doctor trained in Western medicine is the estrogen manually synthesized, such as diethylstilbestrol, Nilestriol, ethinyloestradiol, but
These artificial synthesized estrogen are used for a long time, endometrium hyperplasia, uterine hemorrhage can be caused, in addition cause cervical carcinoma,
Breast cancer, these above-mentioned treatment method toxic side effects are larger.
Chinese medicine thinks the generation of menopausal syndrome with deficiency of kidney-essence, and menses failure, asthenia of essence and blood, it is basic that punching, which is appointed obstructed,
Reason, clinical according to different syndrome type, the characteristics of traditional Chinese medicine treatment can play too many levels, multi-level, multi-angle, multiple target effect.
It is the method effected a permanent cure that marrow is filled out in enriching yin and nourishing kidney, bone strengthening, and soothing liver-qi stagnation, strengthening the spleen and stomach are the plan suited the medicine to the illness, and QI invigorating resolving sputum, activating microcirculation and removing stasis medicinal are then
Prevent the requisite measure that the state of an illness further develops.By treatment, mitigate symptom, shorten the course of disease, adjusts patient's hormone-endocrine system
System function, improves body internal and external environment, to alleviate or mitigate the various symptoms of menopausal syndrome, reaches new dynamic
Balance, therefore a kind of composition treatment menopausal syndrome of Chinese medicine material is selected, have ten for treatment menopausal syndrome
Divide important clinical meaning.
Summary of the invention
It is an object of the invention to overcome the shortcomings of existing treatment method, a kind of improvement Menopause symptom, peace are provided
Composition completely without toxic side effect and preparation and preparation method containing the composition.To achieve the goals above, the present invention mentions
For following technical solution:
A kind of composition of the improvement menopause symptom containing NADH, including following component: NADH, 1- of 1-10 parts by weight
Herba Epimedii secondary aglycon, the chondroitin sulfate of 1-10 parts by weight, the ursodesoxycholic acid of 1-10 parts by weight, the 1-10 weight of 10 parts by weight
The amount Sialic acid of part, the s- Ademetionine of 1-10 parts by weight, the will of 1-10 parts by weight are remote, DHA, 1-10 of 1-10 parts by weight are heavy
Measure the γ-aminobutyric acid of part.
Preferably, composition further includes at least ten kinds of in the auxiliary material of following weight parts: 4-15 parts of rhizoma acori gramineis, 8-20 parts it is red
Chinese herbaceous peony, 20-30 part seed of Oriental arborvitae, 20-30 parts of theanine, 10-20 parts of rhizoma anemarrhenaes, 10-20 parts of centellas, 4-15 parts of folium panacis japonici cum caules, 5-12 parts
And oneself, 5-10 parts of silver wire grass, 5-10 parts of dragon-boat flowers, 5-10 parts of Chinese trumpet creepers, 5-10 parts of conical silene herbs, 4-8 parts of Aquilegia yabeanas, 4-8
Part pyrola, 3-6 parts of Caulis Kadsuraes, 8-20 portions of fructus lyciis, 7-17 parts of radix rehmanniae preparatas, 4-15 parts of Radix Angelicae Sinensis, 4-15 portions of Semen Cuscutaes, 4-15 parts
Rhizoma anemarrhenae, 7-17 part Morinda officinalis, 4-15 parts of Herba Epimedii, 4-15 parts of frutus cnidiis, 4-15 parts of Rhizoma Chuanxiongs, the 7-17 parts of root barks of tree peony, 7-17 parts prolong recklessly
Rope, 7-17 part uncaria, 4-15 parts of mulberry fruits, 4-15 portions of rhizoma cyperis, 4-15 parts of semen coicis, the 4-15 parts of roots of Dahurain angelica, 5-20 parts of dried immature fruit of citron oranges, 5-13
Part fleece-flower root, 15-20 portions of Radix Curcumaes, 5-13 parts of Flos Albiziaes, 10-25 parts of semen ziziphi spinosaes, 10-25 portions of Radix Glycyrrhizaes, 4-15 portions of hawthorn collagen eggs
White powder, 5-20 part jujube powder, 5-30 parts of L-Trps, 5-30 parts of vitamin Cs, 5-13 parts of vitamin Es, 5-30 parts of vitamin B1s,
4-15 parts of vitamin B6s, 4-15 parts of vitamin B12s, 5-30 parts of folic acid.
Preferably, composition further includes that auxiliary material moors golden complex ester, fumaric acid, phosphate, xylitol, microcrystalline cellulose, mistake
Water Span, magnesium stearate, croscarmellose sodium, magnesium hydroxide, pregelatinated form sediment, calcium sulfate, gas phase two
Silica, at least three kinds in lactose.
A kind of preparation of the improvement menopause symptom containing NADH, including the above-mentioned improvement menopause symptom containing NADH
Composition.
The preparation method of the preparation of the above-mentioned improvement menopause symptom containing NADH, includes the following steps:
Raw material is subjected to proportion weighing, relevant auxiliary materials are added, mixes and tablet, pill, particle, capsule or aqua is made.
Preferably, the step specifically includes:
Dried supplementary material is crossed into 30-80 mesh respectively, supplementary material keeps drying, the raw material screened is matched
Relevant auxiliary materials are added in weighing, and 50 DEG C are warming up to after adding water that mixing is sufficiently stirred at 25-40 DEG C, are made described after stirring 1~2h
Preparation.
Preferably, the step specifically includes:
Dried supplementary material is crossed into 30-80 mesh respectively, drying is kept, the raw material screened is subjected to proportion weighing,
Relevant auxiliary materials are added simultaneously, is uniformly mixed, tablet is made.
Preferably, the step specifically includes:
A) it prepares content: dried supplementary material is crossed into 30-80 mesh respectively, supplementary material keeps drying, then will sieve
The raw material chosen carries out proportion weighing, while relevant auxiliary materials are added, and is uniformly mixed；
B) prepare capsule: by above-mentioned prepared content and flexible glue utricule by pelleting, sizing is dry, wash ball, the ball that dries in the air,
It picks up ball and packs and soft capsule is made.
Preferably, the step specifically includes:
(A) auxiliary material component is taken, coarse granule is made, adds 70% ethyl alcohol heating and refluxing extraction, is filtered；Filter residue adds 70% ethyl alcohol again
Heating and refluxing extraction, filtering；Filtrate is merged, the thick paste of relative density 1.35~1.40 is concentrated into, it is spare；
(B) add water to step 1 gained thick paste, heating and refluxing extraction volatile oil divides the volatile oil for taking layering, spare；Volatilization
After oil after the resulting dregs of a decoction and medical fluid coarse filtration, filtrate centrifuge separation takes supernatant and the dregs of a decoction to distinguish spare；
(C) it takes raw material components to merge with the dregs of a decoction obtained by S2 step, adds water to cook and extract secondary rear coarse filtration, filtrate centrifugation point
From extracting to obtain supernatant twice；Supernatant merges with supernatant obtained by S2 step, is concentrated into the thick of relative density 1.35~1.40
Cream, it is spare；
(D) dextrin, superfine silica gel powder are taken, is mixed, is added obtained by S3 step in thick paste, stirs evenly, laying, vacuum drying,
It crushes, dextrin is added, spray into the volatile oil that S2 step obtains, sieving mixes, and is packed into capsule body, the capsule of system.
The composition of the above-mentioned improvement menopause symptom containing NADH improves drug and the health care of menopause symptom in preparation
It is applied in product.
In technical solution of the present invention, each component is matched using be suitable in the composition of the improvement menopause symptom containing NADH
5 ratios, collaboration play a role, safety, without adverse affects comprehensive improvement menopause symptom.Formulation preparation method of the invention
Process flow is simple, the process time is short, no coupling product, and production cost is low, it is easy to accomplish large-scale production.
Specific embodiment
To make technical staff more fully understand the present invention, the embodiment of the present invention is clearly and detailedly illustrated below,
But it is not as a limitation of the invention.Obviously, described embodiment is only a part of the embodiments of the present invention, rather than complete
The embodiment in portion.Based on the embodiments of the present invention, those of ordinary skill in the art are without creative efforts
Every other embodiment obtained, shall fall within the protection scope of the present invention.
The composition for the improvement menopause symptom containing NADH that present invention firstly provides a kind of, including following weight parts
Raw material components: the Herba Epimedii secondary aglycons of NADH, 1-10 parts by weight of 1-10 parts by weight, 1-10 parts by weight chondroitin sulfate,
The ursodesoxycholic acid of 1-10 parts by weight, the Sialic acid of 1-10 parts by weight, the s- Ademetionine of 1-10 parts by weight, 1-10 parts by weight
Remote, 1-10 parts by weight DHA, 1-10 parts by weight of will γ-aminobutyric acid.
Wherein NADH, that is, nicotinamide adenine dinucleotide (reduced nicotinamide adenine
Dinucleotide reduced Coenzyme I, chemical formula C21H27N7O14P2, molecular weight 663.43) are also referred to as.Its oxidised form
For nicotinamide adenine dinucleotide (oxidized nicotinamide adenine dinucleotide, be abbreviated as NAD),
Play the role of transmitting hydrogen and electronics in biological oxidation, play an important role to the growth of maintenance cell, differentiation and energetic supersession.It
Participate in the life processes such as metabolism, the rhythm and pace of moving things, lesion, aging and the apoptosis of body cell.NADH preparation method includes following step at present
It is rapid: to extract the crude extract or its pure enzyme of nicotinamide-nucleotide adenylyltransferase；Immobilization recombinates the transfer of nicotinamide riboside adenylyl
The crude extract of enzyme or its pure enzyme；It is catalyzed with immobilization recombination nicotinamide-nucleotide adenylyltransferase, with nicotinamide nucleotide and three
Adenosine phosphate disodium (ATP) is that substrate prepares nicotinamide adenine dinucleotide.Specifically, NADH's the preparation method is as follows:
By the plasmid pRSET-bmj transformed competence colibacillus bacterial cell of niacinamide-containing nucleosides adenylyl transferase gene
E.coliHB101 is cultivated 24 hours at upper 37 DEG C of Luriabroth (LB) plate (kanamycins containing 100mg/L).Inoculation is single
Be cloned in 5 milliliters of LB liquid mediums (kanamycins containing 100mg/L) in 30 DEG C culture 20-24 hours.Thalline were collected by centrifugation,
And it is suspended in 1 milliliter of 100mM Tris hydrochloride buffer (pH7.5).Then ultrasonic treatment bacterial cell is used.Centrifugation (10
DEG C, 17,800g, 10 minutes) and collect supernatant, as thick leach protein (or crude extract).The nicotinamide riboside adenosine of recombination
Acyltransferase thick leach protein is heat-treated 10 minutes through 70 DEG C, is centrifuged (10 DEG C, 17,800g, 10 minutes) and is collected supernatant, as
Partially purified albumen.
Nicotinamide-nucleotide adenylyltransferase immobilization: take nicotinamide-nucleotide adenylyltransferase thick leach protein or part pure
The albumen of change is diluted to protein content 5- with enzyme buffer liquid (0.02MTris-HCl/0.001MEDTA, pH7.0 solution) is washed
10mg/ml.Enzyme dilution and PB solution (2.0mol/L potassium dihydrogen phosphate, pH7.5) are mixed in equal volume, epoxy type is added and fixes
Change zymophore LX-3000 (10 milligrams of enzymes/gram carrier), is reacted 20 hours for 25 DEG C in shaking table (revolving speed 100rpm).Reaction is completed
Sock filtration is used afterwards, is cleaned 5-6 times with enzyme buffer liquid is washed, is obtained immobilization nicotinamide-nucleotide adenylyltransferase.
Nicotinamide adenine dinucleotide is prepared with immobilization nicotinamide-nucleotide adenylyltransferase:
Prepare substrate solution: trinosin (ATP), the 100mMTris of nicotinamide nucleotide, 10mM containing 5mM
The MgCl2 of hydrochloride buffer and final concentration of 10mM adjusts pH to 7.5.1 milliliter of substrate solution is taken, 0.05 gram of fixation is then added
Change nicotinamide-nucleotide adenylyltransferase, reaction 2-20 hours is carried out in 37 DEG C.Centrifugation (10 DEG C, 17,800g, 15 minutes) is simultaneously received
Collect supernatant.The content of nicotinamide adenine dinucleotide in the supernatant as obtained by high pressure liquid chromatography (HPLC) measurement.Knot
The conversion ratio that fruit nicotinamide nucleotide is converted into nicotinamide adenine dinucleotide is more than 80%.
Herba Epimedii secondary aglycon directlys adopt beta-glucosidase enzymatic hydrolysis using icariin as raw material in above-mentioned raw materials component
Icariin prepares baohuoside Ⅰ, and β-D-Glucose of cutting icariin C-7 prepares the baohuoside Ⅰ of high-purity, reacts
Formula is as follows:
The composition of improvement menopause symptom containing NADH of the invention, further include in the auxiliary material of following weight parts extremely
Few 10 kinds: 4-15 part of rhizoma acori graminei, 8-20 parts of radix paeoniae rubras, the 20-30 parts of seed of Oriental arborvitaes, 20-30 parts of theanine, 10-20 parts of rhizoma anemarrhenaes, 10-20
Part centella, 4-15 parts of folium panacis japonici cum caules, 5-120 parts and oneself, 5-10 parts of silver wires grass, 5-10 parts of dragon-boats flowers, 5-10 parts of Chinese trumpet creepers, 5-10
Part conical silene herb, 4-8 parts of Aquilegia yabeanas, 4-8 portions of pyrolas, 3-6 parts of Caulis Kadsuraes, 8-20 portions of fructus lyciis, 7-17 parts of radix rehmanniae preparatas, 4-
15 parts of Radix Angelicae Sinensis, 4-15 portions of Semen Cuscutaes, 4-15 parts of rhizoma anemarrhenaes, 7-17 parts of Morinda officinalis, 4-15 parts of Herba Epimedii, 4-15 parts of frutus cnidiis, 4-15
Part Rhizoma Chuanxiong, the 7-17 parts of root barks of tree peony, 7-17 parts of rhizoma corydalis, 7-17 parts of uncarias, 4-15 parts of mulberry fruits, 4-15 portions of rhizoma cyperis, 4-15 portions of coix lacryma-jobi
Benevolence, 4-15 part root of Dahurain angelica, the 5-20 parts of dried immature fruit of citron oranges, the 5-13 parts of fleece-flowers root, 15-20 portions of Radix Curcumaes, 5-13 parts of Flos Albiziaes, 10-25 parts of semen ziziphi spinosaes,
10-25 portions of Radix Glycyrrhizaes, 4-15 parts of hawthorn collagen protein powders, 5-20 parts of jujube powders, 5-30 parts of L-Trps, 5-30 parts of vitamin Cs, 5-
13 parts of vitamin Es, 5-30 parts of vitamin B1s, 4-15 parts of vitamin B6s, 4-15 parts of vitamin B12s, 5-30 parts of folic acid.
The composition of improvement menopause symptom of the invention containing NADH simultaneously further includes that auxiliary material moors golden complex ester, rich horse
Acid, phosphate, xylitol, microcrystalline cellulose, sorbitan fatty acid ester, magnesium stearate, croscarmellose sodium, hydrogen
Magnesia, pregelatinated form sediment, calcium sulfate, fumed silica, at least three kinds in lactose.
The composition of improvement menopause symptom disclosed by the invention containing NADH, each component is using suitable compatibility ratio
Example, it is the composition for capableing of a kind of comprehensive climacteric care for multiple links that collaboration, which plays a role,.Specifically: this hair
Bright to be formed using pure Chinese medicine rational proportion, reasonable recipe, compatibility is proper, and NADH and Herba Epimedii secondary aglycon are monarch drug in a prescription, s- in side
Ademetionine enriching yin nourishing liver and kidney, three are monarch drug in a prescription altogether, adjust gonad axis comprehensively, nourish and repair impaired ovary, restore female, pregnant and swash
Plain normal secretions make female incretion remain at equilibrium state, and long-term use delays gonad axis aging periods, postpone menopause
Phase improves sexual function.Sialic acid strengthening the spleen and replenishing qi in ministerial drug, ursodesoxycholic acid enriches blood, blood circulation, and multiple medicine shares, to reach help
The effect of qi and blood, and have certain adjustment effect to endocrine, hypothalamus-hypophysis-gonad axis function can be enhanced.
In adjuvant, while it is defeated to help the remote precise and tiny and sufficient qi and blood that enables to achieve one's ambition with s- Ademetionine, dredging the channel
It send in kidney, thus nourshing kidney consolidating the yin, what congenital essence was able to is supported.γ-aminobutyric acid and DHA are to make medicine, coordinating the drug actions of a prescription, are altogether assistant
Make.The above-mentioned all medicines of monarch are harmonious, altogether the replenishing essence of having reinforce the kidney, tonifying Qi and blood, Heibei provincial opera yin-yang, arrest sweating of promoting blood circulation, calming the liver tranquilizing the mind function,
Also there is apparent menstruation regulating cold dispelling, improve sexual function, anti-aging, improve Abwehrkraft des Koepers, blood-enrich, supporting and hold skin care, improve
The effect of the treatment climacteric syndromes such as sleep, reduction perspiration.
Medicinal material compatibility selected by Chinese materia medica preparation of the present invention is suitable, meets traditional Chinese medicine and modern medicine is theoretical, easy to use, absorbs
Effect is good, without bad and toxic side effect, according to clinical verification, can mitigate symptom, shorten the course of disease, adjust endocrine system function, change
Kind body internal and external environment is suitable for menopausal syndrome clinical treatment to alleviate or mitigate the various symptoms of menopausal syndrome
It is promoted and applied with nursing.
The present invention is put forward for the first time plus specific effectively with NADH and Herba Epimedii secondary aglycon etc. on the basis of conventional formulation
The theory of ingredient, and proved by a large amount of pharmacological evaluations.Current both NADH and Herba Epimedii secondary aglycon are used as health care product
Raw material is used alone, and not yet retrieves any composition that the two is used in conjunction with to preparation at present, the present invention is by deploying
The technical effect of 1+1 > 2 is arrived.Composition of the invention has the effect of strengthening the spleen and replenishing qi, nourshing blood and promoting blood circulation, clearing and activating the channels and collaterals, can show
It writes and promotes patients serum's estrogen level and Estrogen Receptor, increase InhB protein expression, improve ovary weight, promote big
Mouse gonad granulocyte proliferation.For treating ovarian-senescence, significant effect；It is adjustable human endocrine, adjustment hormone,
Increase blood manufacture, improve anaemia, the deficiency of vital energy, enhance cell viability, improves human immunologic function, so that Menopause is postponed,
Alleviate climacteric syndrome symptom.
The preparation of improvement menopause symptom disclosed by the invention containing NADH, more including the above-mentioned improvement containing NADH
The composition of term symptom.Preparation and its preparation side below with reference to embodiment to the above-mentioned improvement menopause symptom containing NADH
Method is further described:
Embodiment 1
(1) raw material: the NADH of 5 parts by weight, the Herba Epimedii secondary aglycon of 5 parts by weight, the chondroitin sulfate of 5 parts by weight, 5 weights
Measure that the ursodesoxycholic acid of part, the Sialic acid of 5 parts by weight, the s- Ademetionine of 5 parts by weight, the will of 5 parts by weight is remote, 5 parts by weight
DHA, 5 parts by weight γ-aminobutyric acid.
(2) auxiliary material:
Including following weight parts: 15 parts of rhizoma acori gramineis, 8 parts of radix paeoniae rubras, 30 parts of seed of Oriental arborvitaes, 20 parts of theanine, 20 parts of rhizoma anemarrhenaes, 10
Part centella, 15 parts of folium panacis japonici cum caules, 5 parts and oneself, 10 parts of silver wire grass, 5 parts of dragon-boats flowers；Auxiliary material further includes mooring golden complex ester, fumaric acid,
Fumed silica.
(3) preparation method:
First dried supplementary material is crossed into 30-80 mesh respectively, keep distribution of particle sizes uniform, mobility is more preferable, former auxiliary
Material keeps drying；
Then the raw material screened is subjected to proportion weighing, relevant auxiliary materials is added, add water to be sufficiently stirred at 25-40 DEG C mixed
After being warming up to 50 DEG C, stirring 1 hour after even, the preparation of the improvement menopause symptom containing NADH is obtained.
Embodiment 2
(1) raw material: the NADH of 10 parts by weight, the Herba Epimedii secondary aglycon of 1 parts by weight, the chondroitin sulfate of 10 parts by weight, 1
The ursodesoxycholic acid of parts by weight, the Sialic acid of 10 parts by weight, the s- Ademetionine of 1 parts by weight, the will of 10 parts by weight is remote, 1 weight
Measure the DHA of part, the γ-aminobutyric acid of 10 parts by weight
(2) auxiliary material:
Including following weight parts: 4 parts of rhizoma acori gramineis, 20 parts of radix paeoniae rubras, 20 parts of seed of Oriental arborvitaes, 30 parts of theanine, 10 parts of rhizoma anemarrhenaes, 20 parts
Centella, 4 parts of folium panacis japonici cum caules, 12 parts and oneself, 5 parts of silver wire grass, 10 parts of dragon-boat flowers, 5 parts of Chinese trumpet creepers, 10 parts of conical silene herbs, 4 parts of North China an animal-drawn seed ploughs
Struggle against dish, 8 portions of pyrolas, 3 parts of Caulis Kadsuraes, 20 portions of fructus lyciis, 7 parts of radix rehmanniae preparatas, 15 parts of Radix Angelicae Sinensis, 4 portions of Semen Cuscutaes, 15 parts of rhizoma anemarrhenaes, 7 parts
Morinda officinalis, 15 parts of Herba Epimedii, 4 parts of frutus cnidiis, 15 parts of Rhizoma Chuanxiongs, 7 parts of root barks of tree peony, 17 parts of rhizoma corydalis, 7 parts of uncarias, 15 parts of mulberry fruits, 4
Part rhizoma cyperi, 15 parts of semen coicis, 4 parts of roots of Dahurain angelica, 20 parts of dried immature fruit of citron oranges, 5 parts of fleece-flowers root, 20 portions of Radix Curcumaes, 5 parts of Flos Albiziaes, 25 parts of semen ziziphi spinosaes, 10
Part Radix Glycyrrhizae, 4 parts of hawthorn collagen protein powders, 20 parts of jujube powders, 5 parts of L-Trps, 30 parts of vitamin Cs, 5 parts of vitamin Es, 30 parts of dimensions
Raw element B1,4 parts of vitamin B6s, 15 parts of vitamin B12s, 5 parts of folic acid.
Auxiliary material further includes mooring golden complex ester, fumaric acid, phosphate, xylitol, microcrystalline cellulose, sorbitan fatty acid
Ester, magnesium stearate, croscarmellose sodium, magnesium hydroxide, pregelatinated form sediment, calcium sulfate, fumed silica.
(3) preparation method:
First dried supplementary material is crossed into 60 meshes respectively, keep distribution of particle sizes uniform, mobility is more preferable, and supplementary material is protected
Hold drying；
Then the raw material screened is subjected to proportion weighing, while relevant auxiliary materials is added, stirred evenly；
The sample mixed is pelletized in granulator, and is dried and then carries out whole grain；
Above-mentioned particle is then put into tablet press machine, adjusts tablet press machine parameter, carries out tabletting, theoretical slice weight is 500mg, most
Film coating, inspection and packaging are carried out afterwards.
Embodiment 3
(1) raw material: the NADH of 1 parts by weight, the Herba Epimedii secondary aglycon of 10 parts by weight, the chondroitin sulfate of 1 parts by weight, 10
The ursodesoxycholic acid of parts by weight, the Sialic acid of 1 parts by weight, the s- Ademetionine of 10 parts by weight, the will of 1 parts by weight is remote, 10 weights
Measure the DHA of part, the γ-aminobutyric acid of 1 parts by weight.
(2) auxiliary material:
Auxiliary material including following weight parts: 7 parts of rhizoma acori gramineis, 15 parts of radix paeoniae rubras, 25 parts of seed of Oriental arborvitaes, 25 parts of theanine, 15 parts know
Mother, 15 parts of centellas, 10 parts of folium panacis japonici cum caules, 10 parts and oneself, 7 parts of silver wire grass, 7 parts of dragon-boat flowers, 7 parts of Chinese trumpet creepers, 7 parts of conical silene herbs, 6 parts
Aquilegia yabeana, 6 portions of pyrolas, 4 parts of Caulis Kadsuraes, 15 portions of fructus lyciis, 12 parts of radix rehmanniae preparatas, 10 parts of Radix Angelicae Sinensis, 10 portions of Semen Cuscutaes, 10 parts
Rhizoma anemarrhenae.
Auxiliary material further includes mooring golden complex ester, fumaric acid, phosphate, xylitol, magnesium stearate, cross-linked carboxymethyl cellulose
Sodium, magnesium hydroxide, pregelatinated form sediment, calcium sulfate, fumed silica.
(3) preparation method:
A, it prepares content: dried supplementary material being crossed into 60 meshes respectively first, supplementary material keeps drying, then will sieve
The raw material chosen carries out proportion weighing, while relevant auxiliary materials are added, and uniformly.
B, prepared by soft capsule body: glycerol and water are added in glue pot, gelatin is then separately added into and correlation prepares auxiliary material,
Flexible glue utricule is made in stirring, vacuum outgas.
C, prepare capsule: by above-mentioned prepared content and flexible glue utricule by pelleting, sizing is dry, wash ball, the ball that dries in the air,
Ball and packaging and other steps are picked up, soft capsule is made.
Embodiment 4
(1) raw material: the NADH of 8 parts by weight, the Herba Epimedii secondary aglycon of 8 parts by weight, the chondroitin sulfate of 8 parts by weight, 4 weights
Measure that the ursodesoxycholic acid of part, the Sialic acid of 4 parts by weight, the s- Ademetionine of 4 parts by weight, the will of 8 parts by weight is remote, 8 parts by weight
DHA, 4 parts by weight γ-aminobutyric acid.
(2) auxiliary material:
Auxiliary material including following weight parts: 10 parts of Rhizoma Chuanxiongs, 10 parts of root barks of tree peony, 10 parts of rhizoma corydalis, 10 parts of uncarias, 10 portions of mulberry fruits
Son, 10 portions of rhizoma cyperis, 10 parts of semen coicis, 10 parts of roots of Dahurain angelica, 15 parts of dried immature fruit of citron oranges, 10 parts of fleece-flowers root, 17 portions of Radix Curcumaes, 10 parts of Flos Albiziaes, 20 parts
Semen ziziphi spinosae, 20 portions of Radix Glycyrrhizaes, 10 parts of hawthorn collagen protein powders, 10 parts of jujube powders, 20 parts of L-Trps, 20 parts of vitamin Cs, 10 parts of dimensions
Raw element E, 20 parts of vitamin B1s, 10 parts of vitamin B6s, 10 parts of vitamin B12s, 20 parts of folic acid.
Auxiliary material further includes mooring golden complex ester, fumaric acid, phosphate, xylitol, microcrystalline cellulose, sorbitan fatty acid
Ester, magnesium stearate, croscarmellose sodium, magnesium hydroxide, pregelatinated form sediment, calcium sulfate, fumed silica.
(3) preparation method:
S1, auxiliary material component is taken, is broken into coarse granule, add 5 times of 70% ethyl alcohol heating and refluxing extraction 2h of amount, filtered；Filter residue adds 3 again
70% ethyl alcohol heating and refluxing extraction 1h of amount again, filtration；Filtrate after above-mentioned filtering is merged, ethyl alcohol is recycled and is concentrated under reduced pressure into 60 DEG C
The thick paste of lower relative density 1.35~1.40, it is spare.
S2, the water that the resulting product of step S1 is added to 7 times of amounts, heating and refluxing extraction volatile oil 4h divide the volatilization for taking layering
Oil, it is spare；The dregs of a decoction and medical fluid coarse filtration, filtrate centrifuge separation, supernatant and the dregs of a decoction are saved backup respectively.
S3, the dregs of a decoction for taking raw material components to obtain with S2 step merge, and it is secondary to add water to cook extraction；Wherein, add 18 for the first time
Amount water extracts 2h again, adds 12 times of amount water extraction 1h for the second time.After adding water to cook extraction, coarse filtration is carried out, filtrate is centrifugated, twice
The supernatant of extraction.The supernatant of extraction is merged with supernatant obtained by S2 step, is concentrated under reduced pressure into relative density at 60 DEG C
1.35~1.40 thick paste, it is spare.
S4: taking dextrin, superfine silica gel powder, mixes, and is added in the alcohol extracting concentration thick paste that above-mentioned S3 step obtains, is sufficiently stirred
Uniformly, laying, vacuum drying, crushing, addition dextrin；The volatile oil that S2 step obtains is sprayed into later, and sieving mixes, and is packed into glue
Capsule.
The preparation of the presently disclosed improvement menopause symptom containing NADH is subjected to clinical trial, to examine its effect
And safety.
Experimental example:
1, case selection:
The clinical observation of menopausal syndrome Patients with 300 Cases is selected, patient is randomly divided into two groups, treatment group 150, the age 44
It is~48 years old, average age 46 years old, the course of disease 1 year~4 years, 3 years average.Control group 150, the age 43~47 years old, average age 45
It is year, the course of disease 1 year~3 years, 2 years average.The course of disease, the degrees of symptoms of two groups of cases are almost the same, no significant difference, and having can
Compare property.
2, medicament selection:
Treatment group patient takes invention formulation, takes orally, 3 tablets once, 3 times a day, in each 1 time in the morning, afternoon and evening, after meal 1 hour
Warm water delivery service, 15 days as a treatment course, usual 3 to 4 courses is effective, and chronic disease needs 5~6 courses for the treatment of.
Control group takes Geng Nian An Capsules, take orally, one time 3,3 times a day.
3, efficacy determination:
(1) cure: hectic fever, perspiration, nocturnal insomnia, the symptoms such as have a dizzy spell disappear；Body recovery from illness, gets well.
(2) effectively: above-mentioned symptom is alleviated, and body recovery from illness is got well.
(3) invalid: illness is unchanged.
4, result:
It takes in the treatment group of invention formulation, cures 108, effective 25, invalid 17, cure rate 72% always has
Efficiency 88.7%.Healing 85 in control group, effective 19, invalid 46, cure rate 56.7%, total effective rate 69.3%.
The above results show that treatment group's cure rate and total effective rate are apparently higher than control group.
Staining effect table using product described in embodiment 1 for 60 volunteers is as shown in table 1:
The staining effect table of 1 volunteer of table
As can be seen from the above data, involutional symptom is varied, different for different individual performances.But
It is visited menopause symptom after product 30 days described in 60 volunteer's embodiments to be also reduced to varying degrees or disappear, especially to bone
The reaction effect of the tissues such as bone, muscle is obvious, can reach therapeutic effect to a variety of symptoms of most people.Only to individual symptoms,
If paramenia, the function and effect of mastoptosis are unobvious, these symptoms are from physiologically in close relations with hormone.
Hereinafter typical case:
1, Wang, female, 45 years old, peasant, Jiangxi people from Fuzhou City.Patient menstrual cycle extends, and reduces through amount, last menopause, and
With symptoms such as hectic fever, perspiration, nocturnal insomnias, examined by our hospital as menopausal syndrome.Once a variety of drugs were taken, effect is not
It is good.1 course for the treatment of of drug therapy of the present invention is taken, symptom is relieved, continues to take 2 course for the treatment of, and the above symptom disappears.Follow-up is extremely
The present does not recur.
2, hair, female, 47 years old, Enterprise Staff, Gansu people from Jinchang.Patient menstrual cycle is irregular, and menostaxis, increases through amount
More or even bleeding dripping urine endlessly, then gradually decreases and stops, and mood swing rises and falls greatly, and with hectic fever, hectic fever is risen from shirtfront,
Incidence is poured into, whole body, manic uneasiness are then involved.Menopausal syndrome is diagnosed as by our hospital.Take Chinese materia medica preparation 3 of the present invention
After a course for the treatment of, body gradually rehabilitation, symptom is relieved, and continues to take 2 course for the treatment of, and the above symptom disappears.Follow-up is not multiple so far
Hair.
3, it is virgin certain, female, 48 years old, teacher, Shaanxi people from Xi'an.Patient's flush region feels scorching hot, and rubefaction is and then quick-fried
Hair property is perspired, and last for several seconds is differed to several minutes, and daily for several times to 30~50 times, night easily inspires seizure frequency, when sense it is dizzy,
Occasionally there is violence impulsive action.Menopausal syndrome is diagnosed as by our hospital.After taking 2 courses for the treatment of of Chinese materia medica preparation of the present invention, symptom
It is clearly better, continues after taking 3 course for the treatment of, symptom disappears, and body recovery from illness is not recurred.
4, face, female, 50 years old, peasant, people from Puyang oilfield of Henan.Patient occurs that temper is big, complaint is more recently, often blames others etc. for
Feature, private prosecution nearest menstrual cycle start irregular, and interval time extends, amount is few, occur having a sleepless night and have a headache, nose heave symptom,
Blood pressure is fluctuated, and with whole body paroxysmal hectic fever sense.Once a variety of drugs were taken, it is ineffective.It is diagnosed as more by our hospital
Term syndrome.After taking 3 courses for the treatment of of Chinese materia medica preparation of the present invention, the above symptom is relieved, and is continued after taking 2 course for the treatment of, disease
Shape disappears, and does not recur.
5, fourth, female, 51 years old, writer, people from Hefei ,Anhui.The recent menopause of patient is flushing, daytime drowsiness, nocturnal insomnia, blood
Pressure increases, and often perspires, the manic uneasiness of heart, excited, emotion-thought abnormal.Menopausal syndrome is diagnosed as by our hospital.It is taking
After 1 course for the treatment of of Chinese materia medica preparation of the present invention, the above symptom improves, and continues after taking 3 course for the treatment of, and the above symptom disappears, and activity is certainly
Such as, there has been no recurrence since follow-up.
6, Lu, female, 54 years old, private owner, people from Yichang.There is paramenia in the recent period in patient, and hectic fever is flushing, warms
Sweating, excited, heart is frenzied endlessly, the symptoms such as paresthesia of skin.Once various drugs were taken, effect is bad.Afterwards
Come our hospital and is diagnosed as menopausal syndrome.After taking 1 course for the treatment of of Chinese materia medica preparation of the present invention, symptom is substantially reduced, then takes 2
After a course for the treatment of, physical recovery is normal.There has been no recurrence since follow-up.
The above description is only a preferred embodiment of the present invention, is not intended to limit the scope of the invention, all at this
Under the inventive concept of invention, is extended using technology made by description of the present invention or recreation is included in patent of the invention
In protection scope.
Claims (10)
1. a kind of composition of the improvement menopause symptom containing NADH, which is characterized in that including following component: 1-10 parts by weight
The Herba Epimedii secondary aglycons of NADH, 1-10 parts by weight, the chondroitin sulfate of 1-10 parts by weight, 1-10 parts by weight ursodeoxycholic
Acid, the will of the s- Ademetionine of the Sialic acid of 1-10 parts by weight, 1-10 parts by weight, 1-10 parts by weight are remote, 1-10 parts by weight
The γ-aminobutyric acid of DHA, 1-10 parts by weight.
2. the composition of the improvement menopause symptom containing NADH according to claim 1, which is characterized in that further include following
It is at least ten kinds of in the auxiliary material of parts by weight: 4-15 parts of rhizoma acori gramineis, 8-20 parts of radix paeoniae rubras, the 20-30 parts of seed of Oriental arborvitaes, 20-30 parts of theanine,
10-20 parts of rhizoma anemarrhenaes, 10-20 parts of centellas, 4-15 parts of folium panacis japonici cum caules, 5-12 parts and oneself, 5-10 parts of silver wires grass, 5-10 part dragon-boats it is colored,
5-10 parts of Chinese trumpet creepers, 5-10 parts of conical silene herbs, 4-8 parts of Aquilegia yabeanas, 4-8 portions of pyrolas, 3-6 parts of Caulis Kadsuraes, 8-20 parts of Chinese hollys
Matrimony vine, 7-17 part radix rehmanniae preparata, 4-15 parts of Radix Angelicae Sinensis, 4-15 portions of Semen Cuscutaes, 4-15 parts of rhizoma anemarrhenaes, 7-17 parts of Morinda officinalis, 4-15 parts of Herba Epimedii,
4-15 parts of frutus cnidiis, 4-15 parts of Rhizoma Chuanxiongs, the 7-17 parts of root barks of tree peony, 7-17 parts of rhizoma corydalis, 7-17 parts of uncarias, 4-15 parts of mulberry fruits, 4-15
Part rhizoma cyperi, 4-15 parts of semen coicis, the 4-15 parts of roots of Dahurain angelica, the 5-20 parts of dried immature fruit of citron oranges, the 5-13 parts of fleece-flowers root, 15-20 portions of Radix Curcumaes, 5-13 portions of silk trees
Flower, 10-25 parts of semen ziziphi spinosaes, 10-25 portions of Radix Glycyrrhizaes, 4-15 parts of hawthorn collagen protein powders, 5-20 parts of jujube powders, 5-30 parts of L- color ammonia
Acid, 5-30 parts of vitamin Cs, 5-13 parts of vitamin Es, 5-30 parts of vitamin B1s, 4-15 parts of vitamin B6s, 4-15 parts of vitamin B12s,
5-30 parts of folic acid.
3. the composition of the improvement menopause symptom containing NADH according to claim 2, which is characterized in that further include auxiliary material
Moor golden complex ester, fumaric acid, phosphate, xylitol, microcrystalline cellulose, sorbitan fatty acid ester, magnesium stearate, crosslinking carboxylic
Sodium carboxymethylcellulose pyce, magnesium hydroxide, pregelatinated form sediment, calcium sulfate, fumed silica, at least three kinds in lactose.
4. a kind of preparation of the improvement menopause symptom containing NADH, which is characterized in that described contain including claim 1-3 is any
There is the composition of the improvement menopause symptom of NADH.
5. a kind of preparation method for the preparation for improving menopause symptom as claimed in claim 4, which is characterized in that including following steps
It is rapid:
Raw material is subjected to proportion weighing, relevant auxiliary materials are added, mixes and tablet, pill, particle, capsule or aqua is made.
6. the preparation method of the preparation according to claim 5 for improving menopause symptom, which is characterized in that the step tool
Body includes:
Dried supplementary material is crossed into 30-80 mesh respectively, supplementary material keeps drying, the raw material screened is carried out proportion title
Relevant auxiliary materials are added in weight, and 50 DEG C are warming up to after adding water that mixing is sufficiently stirred at 25-40 DEG C, and the system is made after stirring 1~2h
Agent.
7. the preparation method of the composition according to claim 5 for improving menopause symptom, which is characterized in that the step
It specifically includes:
Dried supplementary material is crossed into 30-80 mesh respectively, drying is kept, the raw material screened is subjected to proportion weighing, simultaneously
Relevant auxiliary materials are added, is uniformly mixed, tablet is made.
8. the preparation method of the composition according to claim 5 for improving menopause symptom, which is characterized in that the step
It specifically includes:
A) it prepares content: dried supplementary material being crossed into 30-80 mesh respectively, supplementary material keeps drying, then will screen
Raw material carry out proportion weighing, while relevant auxiliary materials are added, are uniformly mixed；
B) it prepares capsule: above-mentioned prepared content and flexible glue utricule being dried by pelleting, sizing, ball is washed, the ball that dries in the air, picks up ball
Soft capsule is made with packing.
9. the preparation method of the composition according to claim 5 for improving menopause symptom, which is characterized in that the step
It specifically includes:
S1, auxiliary material component is taken, coarse granule is made, add 70% ethyl alcohol heating and refluxing extraction, filtered；Filter residue adds 70% ethyl alcohol to heat again
Refluxing extraction, filtering；Filtrate is merged, the thick paste of relative density 1.35~1.40 is concentrated into, it is spare；
S2, add water to step 1 gained thick paste, heating and refluxing extraction volatile oil divides the volatile oil for taking layering, spare；After volatile oil
After the resulting dregs of a decoction and medical fluid coarse filtration, filtrate centrifuge separation takes supernatant and the dregs of a decoction to distinguish spare；
S3: taking raw material components to merge with the dregs of a decoction obtained by S2 step, adds water to cook and extracts secondary rear coarse filtration, filtrate centrifuge separation, and two
It is secondary to extract to obtain supernatant；Supernatant merges with supernatant obtained by S2 step, is concentrated into the thick paste of relative density 1.35~1.40, standby
With；
S4: taking dextrin, superfine silica gel powder, mixes, and is added obtained by S3 step in thick paste, stirs evenly, laying, vacuum drying, crushing,
Dextrin is added, sprays into the volatile oil that S2 step obtains, sieving mixes, and is packed into capsule body, the capsule of system.
10. the composition of -3 any improvement menopause symptoms containing NADH improves climacteric in preparation according to claim 1
It is applied in the drug and health care product of phase symptom.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810514788.6A CN109350652A (en) | 2018-05-25 | 2018-05-25 | The composition of improvement menopause symptom containing NADH, preparation and the preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810514788.6A CN109350652A (en) | 2018-05-25 | 2018-05-25 | The composition of improvement menopause symptom containing NADH, preparation and the preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109350652A true CN109350652A (en) | 2019-02-19 |
Family
ID=65349604
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810514788.6A Withdrawn CN109350652A (en) | 2018-05-25 | 2018-05-25 | The composition of improvement menopause symptom containing NADH, preparation and the preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109350652A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114470138A (en) * | 2022-03-08 | 2022-05-13 | 东莞市倾城姿医疗美容诊所有限公司 | Female private part nursing composition and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101555501A (en) * | 2009-04-28 | 2009-10-14 | 韩山师范学院 | Method for producing Gamma- propalanine by transformation of Lactococcus lactis cells |
| CN101843828A (en) * | 2009-11-25 | 2010-09-29 | 北京绿源求证科技发展有限责任公司 | Chinese medicament for treating climacteric syndromes |
| CN102218089A (en) * | 2011-06-08 | 2011-10-19 | 华夏先葆(北京)中药研究院有限公司 | Chinese medicine preparation capable of increasing bone density and improving osteoporosis and arthralgia |
| CN105920027A (en) * | 2016-07-05 | 2016-09-07 | 仙鹤生物科技（杭州）有限公司 | Application of S-ademetionine in preparation of fetus protection medicines, dysmenorrhea treatment medicines and uterus health products |
| CN106615468A (en) * | 2016-12-29 | 2017-05-10 | 广西桂人堂金花茶产业集团股份有限公司 | Golden camellia plant beverage for replenishing blood and maintaining beauty |
-
2018
- 2018-05-25 CN CN201810514788.6A patent/CN109350652A/en not_active Withdrawn
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101555501A (en) * | 2009-04-28 | 2009-10-14 | 韩山师范学院 | Method for producing Gamma- propalanine by transformation of Lactococcus lactis cells |
| CN101843828A (en) * | 2009-11-25 | 2010-09-29 | 北京绿源求证科技发展有限责任公司 | Chinese medicament for treating climacteric syndromes |
| CN102218089A (en) * | 2011-06-08 | 2011-10-19 | 华夏先葆(北京)中药研究院有限公司 | Chinese medicine preparation capable of increasing bone density and improving osteoporosis and arthralgia |
| CN105920027A (en) * | 2016-07-05 | 2016-09-07 | 仙鹤生物科技（杭州）有限公司 | Application of S-ademetionine in preparation of fetus protection medicines, dysmenorrhea treatment medicines and uterus health products |
| CN106615468A (en) * | 2016-12-29 | 2017-05-10 | 广西桂人堂金花茶产业集团股份有限公司 | Golden camellia plant beverage for replenishing blood and maintaining beauty |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114470138A (en) * | 2022-03-08 | 2022-05-13 | 东莞市倾城姿医疗美容诊所有限公司 | Female private part nursing composition and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101428056A (en) | Health care formulation for improving osteoporosis of female in middle and old age and preparation method thereof | |
| CN109350653A (en) | The composition of improvement menopause symptom containing NMN, preparation and the preparation method and application thereof | |
| CN109700939B (en) | Application of dendrobium officinale leaf, rhizoma polygonati and radish seed in preparation of medicine for treating hypertension | |
| CN104225417A (en) | Traditional Chinese medicine composition with function of assisting improvement of memory and preparation method thereof | |
| CN109364171A (en) | Ovary maintaining composition, preparation containing NADH and DHEA and preparation method thereof | |
| CN103479754B (en) | Hypotensive drug and preparation method thereof | |
| CN102727711A (en) | Traditional Chinese medicine used for treating chronic fatigue syndrome | |
| CN109350652A (en) | The composition of improvement menopause symptom containing NADH, preparation and the preparation method and application thereof | |
| CN103920011A (en) | Pharmaceutical composition for postpartum liver depression qi stagnation type hypogalactia and preparing method thereof | |
| CN115040612A (en) | Composition for regulating hypertension and preparation method thereof | |
| CN106420970A (en) | Pharmaceutical composition for curing premature ovarian failure | |
| CN102068520A (en) | Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN102698064B (en) | Medicament for treating climacteric syndrome | |
| CN104873714A (en) | Menopausal woman syndrome treatment kidney-tonifying and wind evil dispelling climacteric prescription preparation method | |
| CN104940513A (en) | Pharmaceutical composition for treating menopause syndrome | |
| CN105194676B (en) | It is a kind of to treat pharmaceutical composition of hyperlipidemia and preparation method thereof | |
| CN1330325C (en) | Medicine for preventing and curing osteoporosis and its preparing method | |
| CN103798475B (en) | Chinese herbal medicine honey tea (sugar-free particles) for improving sub-health status of perimenopause and preparation technology thereof | |
| CN109123655A (en) | A kind of special doctor's food and preparation method with three high crowd's generation meal regulatory functions | |
| CN109549969A (en) | A kind of flavonoids health care product and preparation method thereof for preventing and treating osteoporosis | |
| CN101019988B (en) | Diabetes treating Chinese medicine | |
| CN102526470B (en) | Medicinal composition for treating primary hypertension | |
| CN107617064A (en) | A kind of Chinese medicine preparation for treating menopausal syndrome and preparation method thereof | |
| CN108743676B (en) | Application method of white peony root in preparation of medicine for treating hypertension | |
| CN106110089A (en) | A kind of Chinese medicine composition treating anxiety, insomnia and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20190219 |
|
| WW01 | Invention patent application withdrawn after publication |